By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk on Wednesday posted second-quarter sales broadly in line with expectations, after last week cutting its ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...